Among the 24 105 patients with metastatic prostate cancer in the Flatiron-Health database, 443 male patients (median [IQR] age, 72 [65-79] years; 10 [2.3%] Asian, 52 [11.7%] Black, 20 [4.5%] Hispanic, 273 [61.6%] White, 35 [7.9%] other, and 53 [12.0%] unknown) with mCRPC, evidence of BRCA1/2 alterations, and who were alive after August 15, 2020, were eligible and included in our analysis. The gene discussed is BRCA1; the disease is metastatic prostate carcinoma.